INTRODUCTION {#s1}
============

Infantile hemangioma (IH) is the most common vascular tumour in childhood, affecting 4% to 5% of infants worldwide \[[@R1]\]. Hemangiomas can show severe progression, which leads to tissue and organ damage that in some cases becomes life-threatening. Clinical treatment varies, including steroids, interferon-alfa, and β-blocker propranolol \[[@R2], [@R3]\]. However, no definitive therapy is available for IH due to the adverse effects of each drug. The risk factors for IH include preterm birth and placental anomalies \[[@R4]\]. In most cases, IH has a unique clinical course with proliferation and involution phases \[[@R5]\]. Numerous genes involved in IH have been identified. However, the pathogenesis and cause of hemangioma remain largely unknown.

The competitive endogenous RNA (ceRNA) hypothesis proposes that RNA transcripts, both coding and non-coding, compete for post-transcriptional control and coregulate each other using microRNA response elements (MREs) \[[@R6], [@R7]\]. Mounting evidence has shown that long non-coding RNAs and messenger RNAs can function as ceRNAs in diverse physiological and pathophysiological states such as myogenesis, melanoma development and cancer \[[@R8]--[@R11]\]. A recent study profiled the expression of distinct long non-coding RNAs (lncRNAs) in infantile hemangioma using microarray analysis and suggested that lncRNAs regulated several genes with important roles in angiogenesis \[[@R12]\]. Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma \[[@R13]\]. Additionally, integrative meta-analysis identified microRNA-regulated networks in infantile hemangioma \[[@R14]\]. However, the role of the ceRNA network in IH has not been elucidated.

In this study, we used Ribo-Zero RNA-Seq and HiSeq to examine the global expression profiles of protein-coding transcripts and non-coding RNAs, including miRNAs and lncRNAs, in IH and matched normal skin controls. Subsequently, gene ontology and pathway analysis displayed that, compared with the matched normal skin controls, many processes over-represented in IH were related to immune system processes, extracellular region regulation, and carbohydrate derivative binding. Further ceRNA network analysis identified 1256 sponge modulators including 87 miRNA-mediated, 70 lncRNA-mediated and 58 mRNA-mediated interactions. Our study may help expand understanding of the roles of the transcriptome, particularly non-coding transcripts, in the mechanisms underlying IH development and provide new research directions.

RESULTS {#s2}
=======

Differential expression profiles and bioinformatics analysis of mRNAs in IH compared with matched normal skin controls {#s2_1}
----------------------------------------------------------------------------------------------------------------------

To profile differentially expressed mRNAs, lncRNAs and miRNAs in IH, we performed RNA-seq on 3 IH samples and matched normal skin controls. We used an Illumina HiseqXTen platform (Illumina, San Diego, CA) for sequencing with (2 × 150 bp) the paired-end module. Fold changes (IH vs. matched normal skin controls) and *p* values were calculated from the normalized expression levels. Hierarchical clustering showed distinguishable mRNA expression patterns among the samples (Figure [1A](#F1){ref-type="fig"}). Up to 144 mRNAs were differentially expressed in the IH samples compared with the matched normal skin controls (fold change ≥2, *P* ≤ 0.05; for a list of differentially expressed mRNAs, see Table [1](#T1){ref-type="table"}). A total of 84 and 60 mRNAs were up-regulated or down-regulated, respectively, by more than two-fold in IH vs. adjacent normal skin tissues (*P* \< 0.05) (Figure [1B](#F1){ref-type="fig"}). KEGG Pathway analysis indicated that the chemokine, NF-kappa B and TGF-beta signalling pathways, as well as cell adhesion molecules (CAMs), were mostly found in the IH samples compared with matched normal skin (Figure [1C](#F1){ref-type="fig"}). In addition, gene ontology (GO) analysis revealed that numerous biological processes, molecular functions and cellular components were involved. Many of the processes that are deregulated in IH were related to immune system processes, carbohydrate derivative binding and extracellular region regulation (Figure [1D](#F1){ref-type="fig"}).

![Expression profiles, Gene ontology (GO) terms and pathways for differentially expressed mRNAs between infantile hemangioma and adjacent normal skin tissues\
(**A**) Hierarchical clustering shows a distinguishable mRNA expression profiling among groups. (**B**) Volcano analysis exhibit differentially expressed mRNAs. Red dots represent up-regulated genes. Green dots illustrate down-regulated genes. (**C**) The top 20 pathways that are associated with the coding genes are listed. The enrichment *Q* value or false discovery rate correct the *p* value for multiple comparisons. *P* values are calculated using Fisher's exact test. The term/pathway on the vertical axis is drawn according to the first letter of the pathway in descending order. The horizontal axis represents the enrichment factor, i.e., (the number of dysregulated genes in a pathway/the total number of dysregulated gene)/(the number of genes in a pathway in the database/the total number of genes in the database). Top 20 enriched pathways are selected according to the enrichment factor value. The selection standards were the number of genes in a pathway ≥4. The different colours from green to red represent the *Q* value (False discovery rate value). The different sizes of the round shapes represent the gene count number in a pathway. (**D**) Most enriched GO terms of the three ontologies that are associated with the differentially expressed coding genes are listed. The horizontal axis represents the gene number. The term/GO on the vertical axis is drawn according to the first letter of the GO in descending order. Red bar represents the biological process, blue bar displays the molecular function, and green bar illustrates the cellular component. Norm or Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.](oncotarget-09-11948-g001){#F1}

###### List of up-regulated and down-regulated mRNAs detected using RNA-seq (FC ≥ 2.83, *P* \< 0.05)

  Gene Name      log2(Tum/Ctr)   up-or-down   *P*\_value     Description
  -------------- --------------- ------------ -------------- -------------------------------------------------------------------------------------------------------------------
  MPO            --6.18461       down         0.00635        myeloperoxidase
  MAGEB2         --5.44166       down         0.0158         MAGE family member B2
  CD8A           --3.35204       down         0.00275        CD8a molecule
  BPI            --3.31652       down         0.0279         bactericidal/permeability-increasing protein
  PGLYRP1        --3.3111        down         0.0412         peptidoglycan recognition protein 1
  LOC283788      --3.17651       down         0.0005         FSHD region gene 1 pseudogene
  IL18R1         --3.02589       down         5.00E-05       interleukin 18 receptor 1
  ADCYAP1        --2.96929       down         0.031          adenylate cyclase activating polypeptide 1
  CXCL13         --2.90547       down         0.02165        C-X-C motif chemokine ligand 13
  MS4A1          --2.78553       down         0.013          membrane spanning 4-domains A1
  SERPINB4       --2.67117       down         0.02235        serpin family B member 4
  MMP12          --2.65413       down         0.02265        matrix metallopeptidase 12
  **PIP**        **--2.63046**   **down**     **0.00195**    **prolactin induced protein**
  LEFTY2         --2.59114       down         0.0361         left-right determination factor 2
  IL13RA2        --2.54593       down         0.04385        interleukin 13 receptor subunit alpha 2
  CSMD3          --2.54162       down         0.00145        CUB and Sushi multiple domains 3
  OR51E1         --2.45263       down         0.0003         olfactory receptor family 51 subfamily E member 1
  PTH2R          --2.32814       down         0.03325        parathyroid hormone 2 receptor
  ADRB3          --2.30562       down         0.0493         adrenoceptor beta 3
  CCL4L2         --2.18575       down         0.01295        C-C motif chemokine ligand 4 like 2
  ERAP2          --2.14489       down         5.00E-05       endoplasmic reticulum aminopeptidase 2
  LTF            --2.14431       down         0.00755        lactotransferrin
  PADI4          --2.08682       down         0.0333         peptidyl arginine deiminase 4
  OR51E2         --2.0297        down         0.01705        olfactory receptor family 51 subfamily E member 2
  FKBP5          --1.98625       down         0.00045        FK506 binding protein 5
  FOLH1          --1.97677       down         0.0032         folate hydrolase (prostate-specific membrane antigen) 1
  CD3G           --1.862         down         0.04425        CD3g molecule
  COL6A5         --1.72947       down         0.0316         collagen type VI alpha 5
  TUBBP5         --1.70945       down         0.0228         tubulin beta pseudogene 5
  CLEC4M         --1.6691        down         0.0217         C-type lectin domain family 4 member M
  S100A9         --1.66717       down         0.0021         S100 calcium binding protein A9
  DIO3           --1.65761       down         0.009          deiodinase, iodothyronine, type III
  LOC645752      --1.64348       down         0.0449         golgin A6 family member A pseudogene
  CD3E           --1.61303       down         0.0266         CD3e molecule
  TNNT3          --1.55491       down         0.00495        troponin T3, fast skeletal type
  S100A8         --1.53696       down         0.0022         S100 calcium binding protein A8
  FUT9           --1.50479       down         0.00195        fucosyltransferase 9
  KRT31          1.50307         up           0.02565        keratin 31
  KRTAP11-1      1.51562         up           0.00975        keratin associated protein 11-1
  KRT85          1.51808         up           0.01765        keratin 85
  KRT81          1.54671         up           0.0292         keratin 81
  KRT34          1.54769         up           0.03615        keratin 34
  EPSTI1         1.574           up           0.0017         epithelial stromal interaction 1 (breast)
  IFI6           1.57562         up           0.0033         interferon alpha inducible protein 6
  IFI35          1.59026         up           0.0059         interferon induced protein 35
  KRTAP3-2       1.61219         up           0.0107         keratin associated protein 3-2
  KC6            1.62074         up           0.0318         keratoconus gene 6
  KRT83          1.65762         up           0.0203         keratin 83
  OAS3           1.69667         up           0.00105        2\'-5\'-oligoadenylate synthetase 3
  USP18          1.72046         up           0.00215        ubiquitin specific peptidase 18
  CYP26B1        1.74162         up           0.00045        cytochrome P450 family 26 subfamily B member 1
  LNX1-AS2       1.74788         up           0.022          LNX1 antisense RNA 2
  IFI44          1.75064         up           0.00015        interferon induced protein 44
  TNFRSF4        1.75918         up           0.0375         tumor necrosis factor receptor superfamily member 4
  LOC339975      1.76055         up           0.02065        uncharacterized LOC339975
  CLDN11         1.7733          up           0.012          claudin 11
  KRT35          1.78149         up           0.0024         keratin 35
  KRT33A         1.80012         up           0.00445        keratin 33A
  OAS2           1.83729         up           0.00145        2\'-5\'-oligoadenylate synthetase 2
  KRT86          1.85155         up           0.0094         keratin 86
  DCD            1.85338         up           0.0401         dermcidin
  ACAN           1.85416         up           0.0002         aggrecan
  PKD1L2         1.90338         up           0.0378         polycystin 1 like 2 (gene/pseudogene)
  SCGB1B2P       1.91013         up           0.01375        secretoglobin family 1B member 2, pseudogene
  CMPK2          1.92066         up           0.00015        cytidine/uridine monophosphate kinase 2
  ADAMTS18       1.95193         up           0.0003         ADAM metallopeptidase with thrombospondin type 1 motif 18
  KRT33B         1.9594          up           0.0128         keratin 33B
  IFIT1          1.97285         up           0.0001         interferon induced protein with tetratricopeptide repeats 1
  MX1            1.99777         up           0.00015        MX dynamin like GTPase 1
  RSAD2          2.07171         up           5.00E-05       radical S-adenosyl methionine domain containing 2
  **IFI44L**     **2.31465**     **up**       **5.00E-05**   **interferon induced protein 44 like**
  LINC00487      2.42803         up           0.0367         long intergenic non-protein coding RNA 487
  **ISG15**      **2.47094**     **up**       **5.00E-05**   **ISG15 ubiquitin-like modifier**
  SULT1A2        2.52975         up           0.02025        sulfotransferase family 1A member 2
  DMC1           2.61725         down         0.00415        DNA meiotic recombinase 1
  FAM132B        2.69101         up           0.0118         \-
  NRIR           2.97361         up           0.0399         negative regulator of interferon response (non-protein coding)
  MTHFD2P1       3.49824         up           0.01845        methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase pseudogene 1
  OR8B2          4.67189         up           0.0423         olfactory receptor family 8 subfamily B member 2
  LOC101929128   4.88337         up           0.0419         uncharacterized LOC101929128

Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Bioinformatics analysis of lncRNAs in IH compared with matched normal skin controls {#s2_2}
-----------------------------------------------------------------------------------

Using the Gencode, RefSeq and UCSC Knowngene databases for non-coding transcripts, we identified 256 differentially expressed lncRNAs with greater than two-fold changes in IH and *p* values \< 0.05 (Figure [2A](#F2){ref-type="fig"}). Of these, 177 were overexpressed and 79 were underexpressed in IH relative to the matched normal skin controls (fold change ≥ 2, *P* ≤ 0.05; for a list of differentially expressed lncRNAs, see Table [2](#T2){ref-type="table"}). LncRNAs (long non-coding RNAs), are defined as greater than 200 nucleotides in length, transcribed by RNA polymerase II (RNA PII), and lacking an open reading frame \[[@R15]\]. LncRNAs have been found to regulate protein-coding (pc) gene expression at both the transcriptional and post-transcriptional levels \[[@R16]\]. To identify the potential mRNA targets of lncRNAs, we use RNAplex to predict the binding of lncRNAs with the antisense target mRNAs. mRNAs 10 kb upstream or downstream of lncRNAs were considered to be the conceivable lncRNA targets and defined as cis target mRNAs. Gene ontology (GO) analysis revealed that cis target mRNAs of differentially expressed lncRNAs were mostly involved in regulatory mechanisms related to transcription, nucleic acid binding transcription factor activity and intracellular components (Figure [2B](#F2){ref-type="fig"}). KEGG Pathway analysis indicated that the MAPK signalling pathway, regulation of autophagy and metabolic pathways were implicated for the cis target mRNAs of differentially expressed lncRNAs (Figure [2C](#F2){ref-type="fig"}).

![Gene ontology (GO) terms and pathways for target mRNAs of differentially expressed lncRNAs between infantile hemangioma and adjacent normal skin tissues\
(**A**) Hierarchical clustering shows a distinguishable lncRNA expression profiling among groups. (**B**) Most enriched GO terms of the three ontologies that are associated with the cis target mRNAs of differentially expressed lncRNAs are listed. (**C**) The top 20 pathways that are associated with the cis target mRNAs of differentially expressed lncRNAs are listed. (B) The horizontal axis represents the gene number. The term/GO on the vertical axis is drawn according to the first letter of the GO in descending order. Red bar represents the biological process, blue bar displays the molecular function, and green bar illustrates the cellular component. (C) The enrichment *Q* value or false discovery rate correct the *p* value for multiple comparisons. *P* values are calculated using Fisher's exact test. The term/pathway on the vertical axis is drawn according to the first letter of the pathway in descending order. The horizontal axis represents the enrichment factor, i.e., (the number of dysregulated genes in a pathway/the total number of dysregulated gene)/(the number of genes in a pathway in the database/the total number of genes in the database). Top 20 enriched pathways are selected according to the enrichment factor value. The selection standards were the number of genes in a pathway ≥4. The different colours from green to red represent the *Q* value (False discovery rate value). The different sizes of the round shapes represent the gene count number in a pathway. Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.](oncotarget-09-11948-g002){#F2}

###### List of up-regulated and down-regulated lncRNAs detected using RNA-seq (FC ≥ 2.83, *P* \< 0.05)

  LncRNAID             GenePos                        log2 (Tum/Ctr)   up-or-down   *p*\_value    LncRNA GeneID
  -------------------- ------------------------------ ---------------- ------------ ------------- -----------------
  TCONS_00116532       chr5:101515283-101519050       --2.74762        down         0.0153        XLOC_074583
  TCONS_00049881       chr16:76805140-76807266        --2.74208        down         0.03405       XLOC_031473
  TCONS_00140157       chr8:111620546-111622506       --2.65655        down         0.02805       XLOC_090179
  TCONS_00108080       chr4:97512593-97516549         --2.51518        down         0.03695       XLOC_068366
  TCONS_00049878       chr16:76790731-76793194        --2.36369        down         0.0245        XLOC_031470
  TCONS_00116531       chr5:101510927-101514253       --2.31673        down         0.03415       XLOC_074582
  TCONS_00125444       chr6:77144877-77146646         --2.19865        down         0.0304        XLOC_080698
  TCONS_00047386       chr15:95209116-95212765        --1.62607        down         0.04695       XLOC_030120
  TCONS_00099093       chr3:117310248-117315662       1.60464          up           0.026         XLOC_061648
  TCONS_00094390       chr3:115548706-115554914       1.63654          up           0.045         XLOC_058344
  **TCONS_00112159**   **chr5:104342703-104346581**   **1.6409**       **up**       **0.0436**    **XLOC_071442**
  TCONS_00099090       chr3:117295535-117304861       1.65949          up           0.0244        XLOC_061645
  TCONS_00125869       chr6:92532111-92539501         1.72153          up           0.01895       XLOC_081015
  TCONS_00092337       chr3:21220256-21226664         1.73612          up           0.01655       XLOC_056961
  TCONS_00036940       chr13:105981280-105999840      1.8649           up           0.0291        XLOC_023137
  TCONS_00022826       chr11:26799455-26802752        1.995            up           0.04175       XLOC_013761
  TCONS_00092345       chr3:21256300-21262413         2.01955          up           0.0065        XLOC_056969
  **TCONS_00125870**   **chr6:92539642-92542765**     **2.05275**      **up**       **0.0118**    **XLOC_081016**
  TCONS_00144439       chr9:13841053-13843543         2.11565          up           0.04215       XLOC_093201
  TCONS_00132673       chr7:94029530-94036098         2.1175           up           0.03365       XLOC_085154
  **TCONS_00088818**   **chr22:11878998-11880540**    **2.12569**      **up**       **0.04895**   **XLOC_054900**
  TCONS_00099084       chr3:117263272-117265249       2.13489          up           0.0322        XLOC_061639
  TCONS_00089156       chr22:23536916-23548776        2.23141          up           0.00335       XLOC_055095
  TCONS_00112938       chr5:136193267-136196387       2.2618           up           0.03135       XLOC_072057
  TCONS_00093724       chr3:76746891-76748374         2.30541          up           0.02505       XLOC_057834
  TCONS_00021543       chr11:124180846-124186471      2.31143          up           0.04245       XLOC_012894
  TCONS_00099092       chr3:117307664-117309582       2.31645          up           0.0351        XLOC_061647
  TCONS_00077659       chr2:12602918-12606149         2.33745          up           0.02735       XLOC_047338
  TCONS_00106552       chr4:19193285-19198298         2.3654           up           0.02555       XLOC_067212
  TCONS_00109906       chr4:187247968-187249825       2.40602          up           0.02915       XLOC_069754
  TCONS_00106583       chr4:19283454-19288399         2.44245          up           0.0258        XLOC_067243
  TCONS_00142894       chr8:98381305-98382530         2.46222          up           0.04195       XLOC_092151
  TCONS_00092347       chr3:21263525-21265295         2.50214          up           0.0228        XLOC_056971
  TCONS_00126048       chr6:104495681-104497908       2.57552          up           0.04765       XLOC_081156
  TCONS_00021618       chr11:124429567-124433267      2.6993           up           0.00985       XLOC_012968
  TCONS_00142579       chr8:89240840-89241898         2.72566          up           0.0405        XLOC_091914
  TCONS_00116213       chr5:86348589-86351550         3.02011          up           0.0077        XLOC_074350
  TCONS_00013577       chr10:64133769-64134877        3.14074          up           0.04865       XLOC_008097
  TCONS_00021614       chr11:124419031-124423063      3.17524          up           0.02925       XLOC_012964
  TCONS_00138013       chr8:9196728-9203476           3.31685          up           0.04465       XLOC_088644
  TCONS_00117017       chr5:130223107-130225700       3.34741          up           0.0088        XLOC_074967
  TCONS_00032295       chr12:91627173-91631603        3.74738          up           0.0054        XLOC_019826
  TCONS_00116260       chr5:86539574-86547371         3.90234          up           0.00265       XLOC_074397
  TCONS_00116261       chr5:86548066-86552126         4.02636          up           0.004         XLOC_074398
  TCONS_00032240       chr12:91452883-91455961        4.05433          up           0.00415       XLOC_019771
  TCONS_00087133       chr21:38178744-38181900        4.62793          up           0.04685       XLOC_053685
  TCONS_00116241       chr5:86436761-86447930         5.05555          up           0.00105       XLOC_074378

Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

Differential expression and bioinformatics analysis of miRNAs in IH compared with matched normal skin controls {#s2_3}
--------------------------------------------------------------------------------------------------------------

We also determines the miRNA expression profiles between IH and matched normal skin controls using HiSeq. One hundred forty-two miRNA candidates were found to be differentially expressed (fold change ≥ 2, *P* ≤ 0.05; for a list of differentially expressed miRNAs, see Table [3](#T3){ref-type="table"}). Of these, 42 miRNAs were up-regulated in IH, whereas 100 miRNAs were down-regulated (Figure [3A](#F3){ref-type="fig"}). To examine the potential biological functions of the miRNAs of interest in IH, we use miRanda, targetscan and PITA software to identify the target genes of known miRNAs with differential expression profiles and extracted intersections or unions of target genes as the final prediction result. Gene ontology (GO) analysis revealed that the target mRNAs of differentially expressed miRNAs were mostly involved in cellular processes, cell components and binding (Figure [3B](#F3){ref-type="fig"}).

###### List of up-regulated and down-regulated miRNAs detected using small RNA-seq (FC ≥ 2.83, *P* \< 0.05)

  miR_name              fold-change(log2 Tum/Ctr)   up-or-down   *p*\_value      sig-lable
  --------------------- --------------------------- ------------ --------------- -----------
  hsa-miR-9-3p          --7.10538475                down         0.000122742     \*\*
  hsa-miR-1303          --6.86430997                down         0.000490585     \*\*
  hsa-miR-223-3p        --3.53749571                down         1.65E-266       \*\*
  hsa-miR-509-3-5p      --3.49076386                down         4.54E-10        \*\*
  hsa-miR-509-5p        --2.50137905                down         0.00149862      \*\*
  hsa-miR-450a-2-3p     --2.22132264                down         0.007574552     \*\*
  hsa-miR-337-5p        --2.13638952                down         0.000918863     \*\*
  hsa-miR-135a-5p       --2.11442989                down         0.012782924     \*
  hsa-miR-513c-5p       --2.11442989                down         0.012782924     \*
  hsa-miR-2355-3p       --2.08634155                down         0.004368201     \*\*
  hsa-miR-202-5p        --1.99889374                down         0.007235532     \*\*
  hsa-miR-200c-5p       --1.99886536                down         0.021358055     \*
  hsa-miR-664b-3p       --1.99886536                down         0.021358055     \*
  hsa-miR-3648          --1.93753391                down         0.001441353     \*\*
  hsa-miR-429           --1.93708866                down         1.47E-256       \*\*
  hsa-miR-26a-1-3p      --1.92492452                down         0.004102228     \*\*
  hsa-miR-3611          --1.92492452                down         0.004102228     \*\*
  hsa-miR-187-3p        --1.89198508                down         0.000828053     \*\*
  **hsa-miR-664a-3p**   **--1.87801528**            **down**     **1.82E-41**    **\*\***
  hsa-miR-383-5p        --1.87335512                down         0.03528718      \*
  hsa-miR-335-3p        --1.84083467                down         7.07E-87        \*\*
  hsa-miR-203a-3p       --1.72913403                down         0               \*\*
  hsa-miR-3912-3p       --1.71155782                down         2.01E-06        \*\*
  hsa-miR-183-3p        --1.69939239                down         0.031012226     \*
  hsa-miR-135b-5p       --1.69929888                down         3.86E-09        \*\*
  hsa-miR-141-5p        --1.69460943                down         6.85E-21        \*\*
  hsa-miR-377-5p        --1.65878433                down         7.03E-08        \*\*
  hsa-miR-16-5p         --1.65065115                down         0               \*\*
  hsa-miR-150-5p        --1.62494834                down         2.07E-49        \*\*
  hsa-miR-627-5p        --1.6233869                 down         0.000309094     \*\*
  hsa-miR-6510-3p       --1.58388025                down         0.000271487     \*\*
  hsa-miR-548p          --1.58387326                down         0.026725738     \*
  hsa-miR-203b-3p       --1.58383438                down         1.74E-09        \*\*
  hsa-miR-195-5p        --1.5823761                 down         0               \*\*
  hsa-miR-141-3p        --1.5772266                 down         0               \*\*
  hsa-miR-200b-3p       --1.57584304                down         0               \*\*
  hsa-miR-944           --1.5589637                 down         4.65E-10        \*\*
  hsa-miR-200b-5p       --1.53135387                down         2.72E-13        \*\*
  hsa-miR-31-5p         --1.5239109                 down         6.16E-159       \*\*
  hsa-miR-183-5p        --1.52252398                down         2.78E-140       \*\*
  hsa-miR-92a-1-5p      --1.52249641                down         0.007046614     \*\*
  hsa-miR-493-5p        --1.51904529                down         6.20E-36        \*\*
  hsa-miR-320d          1.58604035                  up           0.004519782     \*\*
  **hsa-miR-524-3p**    **1.69892552**              **up**       **4.81E-139**   **\*\***
  hsa-miR-7704          1.8311765                   up           0.000268926     \*\*
  hsa-miR-450a-1-3p     2.00090764                  up           0.021183756     \*
  hsa-miR-185-5p        2.03429793                  up           1.64E-39        \*\*
  **hsa-miR-503-5p**    **2.10316253**              **up**       **1.37E-29**    **\*\***
  hsa-miR-122-5p        2.13865463                  up           0.00090565      \*\*
  hsa-miR-1-3p          2.40555691                  up           2.02E-13        \*\*
  hsa-miR-7-5p          2.40555691                  up           2.02E-13        \*\*
  hsa-miR-520e          2.41594514                  up           0.002562365     \*\*
  hsa-miR-1269b         3.39374391                  up           3.56E-05        \*\*
  hsa-miR-1268a         3.8087166                   up           0.000515933     \*\*
  hsa-miR-1268b         3.8087166                   up           0.000515933     \*\*

Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.

![Expression profiles of differentially expressed miRNAs and Gene ontology (GO) terms for target mRNAs of differentially expressed miRNAs between infantile hemangioma and adjacent normal skin tissues\
(**A**) Scatter plot shows the differentially expressed miRNAs. Red dots represent up-regulated miRNAs. Green dots illustrate down-regulated miRNAs. (**B**) Most enriched GO terms of the three ontologies that are associated with the target mRNAs of differentially expressed miRNAs are listed. The term/GO on the horizontal axis is drawn according to the first letter of the GO in ascending order from left to right. The vertical axis represents the percent of genes and gene number. Ctr, matched normal skin tissue; Tum, infantile hemangioma skin tissue.](oncotarget-09-11948-g003){#F3}

Real-time quantitative PCR validation {#s2_4}
-------------------------------------

To validate the RNA-seq data, we randomly selected 9 differentially expressed RNAs (bold-face type in Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}). Real-time quantitative PCR (qRT-PCR) and Bulge-Loop™ qRT-PCR analyses were performed on an additional 9 independent IH skin samples (Table [4](#T4){ref-type="table"}). The results revealed that similar up-regulation or down-regulation patterns were observed in both the RNA-seq and qRT-PCR samples for the 9 RNAs (Figure [4](#F4){ref-type="fig"}, bold in Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}). Therefore, our RNA-seq data were reliable and stable. Among the 9 RNAs, IFI44L, ISG15, TCONS_00088818, TCONS_000112159, TCONS_000125870, miR-503-5p and miR-524-3p were all expressed to a greater extent in the IH tissues than in the matched normal skin controls.

###### Demographic and clinical characteristics of infantile hemangioma (IH) patients (capillary hemangioma)

  No.   Age                Gender   Position               Pathology   Sample use
  ----- ------------------ -------- ---------------------- ----------- ------------
  1     3 months 8 days    Male     Left axilla            IH          RNA-seq
  2     7 months 5 days    Female   Head                   IH          RNA-seq
  3     12 months          Female   Left Abdomen           IH          RNA-seq
  4     9 months           Female   Right thoracic wall    IH          qRT-PCR
  5     5 months           Male     Thoracic wall          IH          qRT-PCR
  6     6 months 9 days    Female   Occiput                IH          qRT-PCR
  7     8 months 13 days   Female   Right posterior neck   IH          qRT-PCR
  8     10 months          Female   Left abdomen           IH          qRT-PCR
  9     4 months           Female   Right thoracic wall    IH          qRT-PCR
  10    11 months          Male     Thoracic wall          IH          qRT-PCR
  11    8 months 21 days   Female   Occiput                IH          qRT-PCR
  12    5 months 12 days   Female   Head                   IH          qRT-PCR

![The differential expression of mRNAs, lncRNAs and miRNAs between additional IH skin (*n* = 9) and matched normal skin tissues (*n* = 9)\
mRNAs and lncRNAs expression were validated by quantitative real-time PCR using 2^(--△△Ct)^ method. miRNAs expression was validated by Bulge-Loop™ qRT-PCR. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01.](oncotarget-09-11948-g004){#F4}

The ceRNA network construction {#s2_5}
------------------------------

Recently, lncRNAs and mRNAs have been demonstrated to be function as ceRNAs in diverse physiological and pathophysiological states. It is known that mRNAs or lncRNAs can bind miRNAs through microRNA response elements (MREs). Therefore, we use rna22 and targetscan to screen the lncRNAs and mRNAs with MREs. To ascertain the associations of differentially expressed lncRNAs and miRNAs with mRNAs, based on the 142 differentially expressed miRNAs, 144 differentially expressed mRNAs, and 256 differentially expressed lncRNAs, an lncRNA-miRNA-mRNA correlation network was constructed (Figure [5](#F5){ref-type="fig"}). The network displayed the associations among 87 miRNAs, 70 lncRNAs and 58 mRNAs mediated interactions. For example, miR-26a-1-3p could bind to lncRNAs TCONS_00074621 and mRNA CD24, miR-24-3p bind with TCONS_00000006 and LEFTY2, moreover, miR-514a-3p bind to TCONS_00040753 and FLT1. As shown in Figure [5](#F5){ref-type="fig"}, one miRNA was associated with one to tens of mRNAs and vice versa. One lncRNA was related to one to tens of miRNAs. In total, 1256 sponge modulators participated in 87 miRNA-mediated, 70 lncRNA-mediated and 58 mRNAs' transcripts-mediated interactions. These findings indicated that the expression profiles of miRNAs, mRNAs and lncRNAs were significantly correlated.

![The ceRNA network of the differentially expressed miRNA-mediated lncRNAs and mRNAs interactions\
Red color represents the mRNA name, green color displays the lncRNA name, and orange color illustrates the miRNA name. Taken TCONS_00126150 \| CD24 and TCONS_00126153 \| CD24 as an example, the TCONS\_ number before \| means the ID number of each transcript, one gene has many transcripts.](oncotarget-09-11948-g005){#F5}

DISCUSSION {#s3}
==========

Currently, with the advent of next-generation sequencing technologies, RNA-Seq is gradually replacing microarrays for the detection of transcript expression profiling. IH is one of the most common tumors diagnosed in young children. The pathogenesis of hemangioma is largely unknown due to its sophisticated etiology. Although a lot of papers report the RNA networks in IH \[[@R12], [@R14], [@R17]--[@R19]\], those work all used microarrays methods. In this study, we used Ribo-Zero RNA-Seq and HiSeq means to examine the global expression profiles of protein-coding transcripts and non-coding RNAs, including miRNAs and lncRNAs, in IH and matched normal skin controls. Totally, 144 mRNAs, 256 lncRNAs and 142 miRNAs were found to be differentially expressed (fold change ≥ 2, *P* ≤ 0.05) in IH compared to matched normal skin. Further integrated ceRNA network analysis revealed that 353 sponge modulators participate in 39 miRNA, 29 lncRNA and 147 mRNA mediated interactions.

Competitive endogenous (ce) RNAs cross-regulate each other through sequestration of shared microRNAs and form complex regulatory networks based on their microRNA signatures \[[@R20]\]. Genome-wide transcriptional profiling of vessels from proliferating and involuting hemangiomas has been used to identify differentially expressed genes \[[@R19]\]. A lncRNA microarray study reported that a large number of genes are differentially expressed in IH \[[@R12]\]. Integrative meta-analysis identifies miRNA-regulated networks in IH \[[@R14]\]. Here, based on RNA-seq technology, using IH tissues and matched normal skin, we presented a new ceRNA network that determined the functions of particular miRNAs, lncRNAs and mRNAs in IH development (Figure [5](#F5){ref-type="fig"}). Alterations in one ceRNA may have striking effects on the integrated ceRNA and transcriptional networks. Taken miR-664a-3p as an example, it was down-regulated in IH tissues from the small RNA-seq data (Table [3](#T3){ref-type="table"}). Bulge-Loop™ qRT-PCR demonstrated that expression of miR-664a-3p was decreased in another nine IH tissues (Figure [4](#F4){ref-type="fig"}). The ceRNA network analysis revealed that three lncRNAs TCONS_00020616, TCONS_00058199 and TCONS_00108595 could bind to miR-664a-3p. Moreover, nine mRNAs including ADCYAP1, CSMD3, IL18R1, IKZF3, CD8A, FGL2, FUT9, IGF2BP1, and TMEM38B were predicted to bind with miR-664a-3p (Figure [5](#F5){ref-type="fig"}). This ceRNA network indicated that those nine mRNAs' expression could be regulated by miR-664a-3p, and three lncRNAs TCONS_00020616, TCONS_00058199, TCONS_00108595 could compete to bind with miR-664a-3p and then affect those nine mRNAs' expression.

The pathogenesis of IH has been linked to pathways affecting angiogenesis and vasculogenesis \[[@R21]\]. Those microarray analyses concluded that angiogenin may be a useful serum marker for hemangiomas \[[@R22]\], IH endothelial cells (HEMECs) reflects a pro-proliferative cell type with altered adhesive characteristics \[[@R17]\], proliferating hemangiomas display increased expression of genes involved in endothelial-pericyte interactions, as well as those involved in neural and vascular patterning \[[@R19]\], lncRNAs likely regulate several genes in angiogenesis \[[@R12]\], miRNA-mRNA expression networks display that deregulated genes play roles in cell growth and differentiation, cell signaling, angiogenesis and vasculogenesis \[[@R14]\]. In the present study, using RNA-seq technology, we found that deregulated mRNAs related to immune system processes, carbohydrate derivative binding, extracellular region regulation, chemokine, NF-kappa B and TGF-beta signalling pathways, as well as cell adhesion molecules (CAMs) (Figure [1](#F1){ref-type="fig"}). Moreover, cis target mRNAs of differentially expressed lncRNAs were mostly involved in regulatory mechanisms related to transcription, nucleic acid binding transcription factor activity, intracellular components, MAPK signalling pathway, regulation of autophagy and metabolic pathways (Figure [2](#F2){ref-type="fig"}). Additionally, target mRNAs of differentially expressed miRNAs were mostly involved in cellular processes, cell components and binding (Figure [3](#F3){ref-type="fig"}). These results are partly consistent with those of previous studies in that CAMs are involved. Besides, RNA-seq data show some new findings in that regulation of autophagy and metabolic pathways, TGF-beta, NF-kappa B signalling and chemokine signalling were involved in the pathogenesis of IH.

Endothelial TGF-β signalling has been implicated in the regulation of angiogenesis \[[@R23]\]. Expression of NF-kappa B target genes was demonstrated in proliferating IH. Targeting NF-kappa B in infantile hemangioma-derived stem cells reduced VEGF-A expression \[[@R24]\]. The chemokine CXCL-14 has been reported to be involved in the occurrence and development of infantile hemangioma \[[@R25]\]. Our RNA-seq data found that TGF-beta, NF-kappa B signalling and chemokine signalling were involved in the pathogenesis of IH. The results are consistent with those of previous studies, which suggested that the RNA-seq data are reliable.

By carefully comparing our data with other's, IGF2, FOXF1 and EGFL7 were reported to be up-regulated in IH, FOXC1 and EGFR were down-regulated in IH \[[@R12]\]. In this study, we found that IGF2 mRNA-binding proteins (IGF2BPs) including IGF2BP1, IGF2BP2 and IGF2BP3 were all downregualted in IH. Although recent publication reported that results obtained by RNA-seq and microarrays were highly reproducible \[[@R26]\], some discrepancy may be existed in the differentially expressed RNAs. Therefore, further demonstrating the function of particular RNA in IH development is urgently needed. In addition, larger samples are needed to perform receiver operating characteristic (ROC) curve analysis to prove that some of the IH RNAs are promising biomarkers.

Taken together, understanding the functional interactions among lncRNAs, miRNAs and mRNAs could lead to new explanations for IH disease pathogenesis \[[@R7]\]. Further elucidating the underlying mechanisms of the functions of miRNAs, lncRNAs and mRNAs in IH would be helpful in revealing the biological aetiology and potentially provide useful information for IH evaluation and treatment.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

This study was approved by the Medical Ethics Committee of the Obstetrics and Gynaecology Hospital affiliated with Nanjing Medical University (No. \[2015\] 91). Children with IH underwent surgery at out hospital. The IH samples and matched normal skin controls were collected from patients who underwent surgery and whose parents provided written consent.

Tissue samples {#s4_2}
--------------

Proliferating capillary infantile hemangioma (IH) and matched normal skin tissues were obtained from 12 different patients who were admitted to the Obstetrics and Gynaecology Hospital affiliated with Nanjing Medical University for IH removal. Patient information is listed in Table [4](#T4){ref-type="table"}. A diagnosis of proliferative infantile hemangioma was confirmed by routine pathological examination. The collected skin samples were immediately frozen in liquid nitrogen for total RNA preparation.

Total RNA isolation {#s4_3}
-------------------

Total RNA was extracted from biopsy samples using the Qiagen RNeasy mini kit (Qiagen, Valencia, CA). After ribosomal RNA depletion, RNA-seq libraries were prepared using ScriptSeq complete kits from Epicenter (Madison, WI). RNA purity was assessed using the Nano Photometer^®^ spectrophotometer (IMPLEN, CA, USA), and RNA concentration was measured using the Qubit® RNA Assay Kit in Qubit^®^ 2.0 Flurometer (Life Technologies, CA, USA). RNA integrity was assessed using the RNA Nano 6000 Assay Kit from the Bioanalyser 2100 system (Agilent Technologies, CA, USA).

Library preparation, quality examination and sequencing for mRNAs and lncRNAs {#s4_4}
-----------------------------------------------------------------------------

The sequencing libraries were prepared following manufacturer recommendations from the VAHTS™ Total RNA-seq (H/M/R) Library Prep Kit for Illumina^®^. The details of library construction were patented by the company (Vazyme, China). After cluster generation, the libraries were sequenced on an Illumina Hiseq X10 platform, and 150-bp paired-end reads were generated.

Raw reads in fastq format were first processed using in-house perl scripts. Clean reads were obtained by removing reads with adapters, reads in which unknown bases were more than 5% and low quality reads (if the percentage of low quality bases was greater than 50% in a given read, we defined the low quality base to be the base whose sequencing quality was no more than 10). At the same time, Q20, Q30, and GC contents were calculated for the clean reads. All downstream analyses were based on the clean reads.

The reference genome and gene model annotation files were downloaded directly from the genome website. The reference genome index was built using Bowtie (v2.1.0) \[[@R27]\], and the paired-end clean reads were aligned to the reference genome using TopHat (v2.1.1) \[[@R28]\].

Transcriptome assembly, lncRNA prediction and target gene prediction {#s4_5}
--------------------------------------------------------------------

The mapped reads from each sample were assembled using Cufflinks (v2.2.1) \[[@R29]\] with a reference-based approach. Cufflinks uses a probabilistic model to simultaneously assemble and quantify the expression levels of a minimal set of isoforms, which provides a maximum likelihood explanation of the expression data in a given locus. Then, Cuffmerge was used to merge these sample assemblies into a master transcriptome, which was compared to known transcripts via Cuffcompare. The lncRNAs were predicted by several strict steps based on RNA structural characteristics and non-coding properties. The steps were as follows: 1) transcripts, not in any class code of " j, i, o, u, x ", were filtered out; 2) transcripts shorter than 200 bp were filtered out; 3) transcripts aligned to sequences in the NONCODE database \[[@R30]\] by blastn were identified as known lncRNAs; 4) the retained transcripts (known lncRNAs were not included) were used to predict protein coding potential by Coding Potential Calculator (CPC) \[[@R31]\] and TransDecoder (<http://transdecoder.github.io/>), transcripts with coding potential were removed, and those without coding potential were identified as novel lncRNAs. The known lncRNAs and novel lncRNAs were together used for subsequent analyses.

LncRNAs can negatively or positively affect expression of the downstream gene via an upstream noncoding promoter. Genes within 10 kb upstream or downstream of lncRNAs were abstracted by bedtools (<http://bedtools.readthedocs.io/en/latest/>) as lncRNA target genes. However, antisense lncRNAs can regulate overlapping sense transcripts. Transcripts that overlapped with LncRNAs on the opposite strand were also identified as lncRNA target genes, and the interactions between lncRNAs and transcripts were revealed by RNAplex \[[@R32]\].

Quantification of gene expression levels and differential expression analysis {#s4_6}
-----------------------------------------------------------------------------

Cuffdiff (v2.2.1) \[[@R33]\] was used to calculate FPKMs for both lncRNAs and coding genes in each group. Gene FPKMs were computed by summing the FPKMs of the transcripts in each gene group. FPKM stands for "fragments per kilobase of exon per million fragments mapped" and is calculated based on the length of the fragments and the reads count mapped to each fragment.

Cuffdiff (v2.2.1) provides statistical routines for determining differential expression in digital transcripts or gene expression datasets using a model based on a negative binomial distribution. Transcripts or genes with corrected *p* values less than 0.05 and absolute values of log2 (fold change) \<1 were classified as significantly differentially expressed.

Small RNA sequencing and bioinformatics analysis {#s4_7}
------------------------------------------------

Total RNA was separated by 15% agarose gels to extract the small RNA (18--30 nt). After ethanol precipitation and centrifugal enrichment of small RNA samples, the library was prepared according to the methods and processes described in the Small RNA Sample Preparation Kit (Illumina, RS-200-0048). Insert size was assessed using the Agilent Bioanalyser 2100 system (Agilent Technologies, CA, USA), and after the insert size was consistent with expectations, qualified insert size was accurately quantitated using a Taqman fluorescence probe from the AB Step One Plus Real-Time PCR system (Library valid concentration \> 2 nM). The qualified libraries were sequenced using an Illumina Hiseq 2500 platform, and 50-bp single-end reads were generated.

First, the tags were mapped to the reference genome by SOAP \[[@R34]\] to analyse their distributions within the genome and were aligned to the miRBase database \[[@R35]\] using blast. The tags were identified as known miRNAs when they satisfied the following criteria: 1) there were no mismatches when aligned to the miRNA precursors in the miRBase database; 2) based on the first criteria, the tags were aligned to the mature miRNAs in the miRBase database with at least 16-nt overlap while allowing offsets. The miRNA target genes were predicted using two software programs (targetscan and miRanda) as we previously described \[[@R36]\], and the intersection of target genes (the intersections were the same target genes of the same miRNAs) were the final target genes.

The miRNA expression levels were measured by "Transcripts Per Kilobase Million" (TPM).$$\mathit{TPM} = 10^{6}{C/L}$$where C is the read count of a miRNA and L is the total count of clean reads in sample.

Differentially expressed miRNAs were evaluated using the following statistical tests:

1\) Statistical algorithm developed by Audic and Claverie (1997) \[[@R37]\]$$P\left( {y\left| x \right.} \right) = \left\lbrack \frac{N_{2}}{N_{1}} \right\rbrack^{y}\frac{\left( {x + y} \right)!}{x!y!\left\lbrack {1 + \frac{N_{2}}{N_{1}}} \right\rbrack^{({x + y + 1})}}$$where N~1~ is the total clean reads from sample 1, N~2~ is the total clean reads from sample 2, x is the number of reads from sample 1 mapped to miRNA A and y is the number of reads from sample 2 mapped to miRNA A.

Gene Ontology (GO) and KEGG enrichment analysis {#s4_8}
-----------------------------------------------

GO enrichment analysis of differentially expressed genes or target genes of differentially expressed lncRNAs was implemented using a perl module (GO::TermFinder) \[[@R38]\]. GO terms with corrected *p* values less than 0.05 were considered to be significantly enriched among the differentially expressed genes or the target genes of differentially expressed lncRNAs. R functions (phyper and qvalue) were used to test for statistical enrichment of the differentially expressed genes or target genes of the differentially expressed lncRNAs among the KEGG pathways. KEGG pathways with corrected *p* values less than 0.05 were considered to be significantly enriched among the differentially expressed genes or the target genes of the differentially expressed lncRNAs.

Validation of RNA-seq data {#s4_9}
--------------------------

To confirm the RNA-seq data, the expression profiles of randomly selected mRNAs and lncRNAs were tested in another 9 IH patients using quantitative real-time polymerase chain reactions (qRT-PCR) with the SYBR green method on an Applied Biosystems ViiA™ 7 Dx (Life Technologies, USA). Patient information is listed in Table [4](#T4){ref-type="table"}. The sequences of the specific PCR primer sets used for qRT-PCR are listed in Table [5](#T5){ref-type="table"}. The RNA expression levels were normalized to the internal control gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), using the 2^(--△△Ct)^ method as we previously described \[[@R39]\]. Three selected miRNAs were further examined by Bulge-Loop™ qRT-PCR according to the manufacturer's protocol (RIBOBIO, Guangzhou, China) with the SYBR green method on an Applied Biosystems ViiATM 7 Dx (Life Technologies, USA). The miRNA expression levels were normalized to u6 (RIBOBIO, Guangzhou, China), using the 2^(--△△Ct)^ method.

###### Details of primer pairs used in analysis of mRNAs and lncRNAs expression by qRT-PCR

  Gene name        Forward primer (5′-3′)    Reverse primer (5′-3′)
  ---------------- ------------------------- ------------------------
  IFI44L           ACAGAGCCAAATGATTCCCTATG   TCGATAAACGACACACCAGTTG
  ISG15            CGCAGATCACCCAGAAGATCG     TTCGTCGCATTTGTCCACCA
  PIP              GTCAGTACGTCCAAATGACGAA    CTGTTGGTGTAAAAGTCCCAGT
  TCONS_00088818   GCCTTGTGGTGTCTCCTCAG      TAGACCAGGCGTCATAGCAGAA
  TCONS_00112159   GAAACAGCCACGGAGGGAAC      GATTTCTGCAATGCCGTGCC
  TCONS_00125870   CCTAGAACCAGGGGCCACAA      TTTGCTGGGCACTCTGTAGC

CeRNA network analysis {#s4_10}
----------------------

The miRanda and TargetScan assessments were used to identify ceRNAs (competing endogenous RNAs, including protein-coding messenger RNAs, long non-coding RNAs and circular RNAs), containing microRNA response elements (MREs). Then, ceRNAs with common miRNAs were selected to predict the global interactions between miRNAs and ceRNAs. Additionally, the ceRNAs with common miRNAs that were up- or down-regulated by miRNAs were abstracted based on differential expression to predict the co-regulated interactions of miRNAs and ceRNAs. The co-regulated ceRNA network was generated by Cytoscape (V. 3.4.0) \[[@R40]\].

Statistical analysis {#s4_11}
--------------------

Data were analysed using the SPSS 20.0 software package (SPSS, Chicago, IL, USA) with an independent-samples *T* test performed between the two groups. All values are represented as the mean ± standard deviation (SD) from at least three independent experiments. Statistical significance was defined as *P* \< 0.05.
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